SOURCE: Healtheuniverse, Inc.

June 13, 2007 09:03 ET

Healtheuniverse Announces Patented Intellectual Property Utilizing Adult Stem Cells, Offers Alternative to Human Embryonic Stem Cells for Medical Treatment

COVINA, CA--(Marketwire - June 13, 2007) - Healtheuniverse Inc. (PINKSHEETS: HLUN), a biotechnology development firm engaged in research, development and commercialization of regenerative medicine therapies utilizing non-embryonic adult stem cells announced today that patented intellectual property developed by Healtheuniverse may lead to the development of various cell lines that will be utilized to cultivate cells amalgamate to form functional human tissue. These unique cell lines offer an alternative to human embryonic stem cells for medical treatments.

Major commercial applications for these progenitor cell lines will be utilized for both non-surgical and surgical areas. Non-surgical applications will be focused on skin rejuvenation and minor wound reparative processes. Surgical applications will address major wound repair and reconstructive areas such as formation of new skin and bone.

Vipul Dev M.D., Chief Executive Officer of Healtheuniverse stated, "Our research is a promising example that adult stem cells are not necessarily locked into their current fate and we have the potential to reprogram them into becoming other cell types. It is unlikely that one source of stem cells can be used to treat all medical problems and diseases, but different clinical applications could be addressed by using adult cells taken from adipose tissue, without the same ethical concerns associated with embryonic stem cells. In addition adult stem cells have the potential to avoid a critical obstacle posed by embryonic stem cell use -- the possibility that a patient's body could reject the foreign cells."


HEALTHeUNIVERSE Inc. is engaged in research, development and commercialization of regenerative medicine therapies utilizing non-embryonic adult stem cells for use in plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in disease related commercial applications. More information on Healtheuniverse is available online at

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information

  • For more information, please contact:
    Healtheuniverse, Inc.
    Investor Relations
    Email Contact